Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients

详细信息    查看全文

• 作者：Caroline Foreman ; Paul Russo ; Noelene Davies ; Pravin Hissaria ; Susanna Proudman ; Tiffany Hughes and Vidya Limaye
• 刊名：Internal Medicine Journal
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：47
• 期：1
• 页码：112-115
• 全文大小：455K
• ISSN：1445-5994

文摘

In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.